High score for molecular coincidence detection technology (MCD) imaging in lung cancer trial
This article was originally published in Clinica
Executive Summary
ADAC Labs' molecular coincidence detection technology (MCD) could reduce unnecessary surgeries on cancer patients by indicating those who have inoperable tumours, the results of a new study suggest. The technology can distinguish malignant from benign lesions, says ADAC.